VVTMF (VVT Med) EBITDA per Share: $-0.04 (TTM As of Sep. 2025)


VVTMF VVT Med Inc VVTMF
6 GF Score
Price $0.02
! 4 Warning Signs
View Full Analysis

What is VVT Med EBITDA per Share?

VVT Med VVTMF 6 EBITDA per Share is $-0.04 as of Sep. 2025. GuruFocus rates VVTMF with a GF Score™ of 6/100. The stock has 4 warning signs investors should review. Among 695 Medical Devices & Instruments companies, VVT Med ranks worse than 143884.75% on this metric.

VVT Med's EBITDA per Share for the three months ended in Sep. 2025 was $-0.03. Its EBITDA per Share for the trailing twelve months (TTM) ended in Sep. 2025 was $-0.04.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for VVT Med's EBITDA per Share or its related term are showing as below:

VVTMF's 3-Year EBITDA Growth Rate is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 7.9
* Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.

VVT Med's EBITDA for the three months ended in Sep. 2025 was $-2.15 Mil.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.


VVT Med  (OTCPK:VVTMF) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


VVT Med EBITDA per Share Related Terms


VVT Med EBITDA per Share Historical Data

* Premium members only.

The historical data trend for VVT Med's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

VVT Med EBITDA per Share Chart

VVT Med Annual Data
Trend Dec22 Dec23 Dec24
EBITDA per Share
-0.03 -0.03 -0.01

VVT Med Quarterly Data
Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
EBITDA per Share Get a 7-Day Free Trial Premium Member Only -0.01 0.00 -0.01 -0.01 -0.03
VVTMF
6GF Score
VVT Med Inc VVTMF
EBITDA per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

VVT Med EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

VVT Med's EBITDA per Share for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA per Share(A: Dec. 2024 )
=EBITDA/Shares Outstanding (Diluted Average)
=-0.537/66.640
=-0.01

VVT Med's EBITDA per Share for the quarter that ended in Sep. 2025 is calculated as

EBITDA per Share(Q: Sep. 2025 )
=EBITDA/Shares Outstanding (Diluted Average)
=-2.15/66.311
=-0.03

EBITDA per Share for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA per Share →
What does a EBITDA per Share of $-0.04 mean?
VVT Med (VVTMF) has a EBITDA per Share of $-0.04 as of Sep. 2025. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on VVT Med and its competitors. According to the industry distribution chart, VVT Med ranks #999999 out of 695 companies in the Medical Devices & Instruments industry.
Is VVT Med's EBITDA per Share too high?
VVT Med's current EBITDA per Share is $-0.04. Based on the distribution chart, VVT Med ranks #999999 out of 695 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, VVT Med has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does VVT Med's EBITDA per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, VVT Med ranks #999999 out of 695 companies for EBITDA per Share. This places VVT Med in the lower half of its industry. The industry median EBITDA per Share is 7.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA per Share for a Medical Devices & Instruments company?
The median EBITDA per Share among Medical Devices & Instruments companies is 7.90, based on 695 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA per Share significantly above this median, while those in the bottom quartile fall well below. However, EBITDA per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA per Share mean?
A high EBITDA per Share can signal that a stock is expensive relative to its fundamentals. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on VVT Med and its competitors. For the Medical Devices & Instruments industry, the median EBITDA per Share is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VVT Med's current EBITDA per Share is $-0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VVT Med stock overvalued right now?
VVT Med (VVTMF) has a current EBITDA per Share of $-0.04. The current EBITDA per Share is $-0.04. VVT Med's overall GF Score™ is 6/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA per Share calculated?
EBITDA per Share is calculated from a company's financial statements. For VVT Med (VVTMF), the current EBITDA per Share is $-0.04 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

VVT Med Business Description

Other Exchanges VVTM:Canada
Address 700 West Georgia Street, Suite 2200, Vancouver, BC, CAN, V7Y 1K8
VVT Med Inc is a medical device company, focused on developing and commercializing a range of minimally invasive technologies for treating varicose veins. VVT's research and development activities are based in Israel. The company proudly boasts three products within its portfolio that have achieved commercial production status and are currently available in the market. These products have undergone meticulous design processes, obtaining regulatory approvals across multiple countries.
6GF Score

Get the complete analysis for VVTMF

EBITDA per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.02
Price